Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vaxcyte (PCVX) Current Deferred Revenue (2019 - 2020)

Vaxcyte (PCVX) has 2 years of Current Deferred Revenue data on record, last reported at $14000.0 in Q4 2020.

  • On a quarterly basis, Current Deferred Revenue fell 26.32% to $14000.0 in Q4 2020 year-over-year; TTM through Dec 2020 was $14000.0, a 26.32% decrease, with the full-year FY2020 number at $14000.0, down 26.32% from a year prior.
  • Current Deferred Revenue reached $14000.0 in Q4 2020 per PCVX's latest filing, down from $27000.0 in the prior quarter.
  • Over the last five years, Current Deferred Revenue for PCVX hit a ceiling of $27000.0 in Q3 2020 and a floor of $14000.0 in Q4 2020.